Lantheus Holdings, Inc.
LNTH
Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, a microbubble ultrasound enhancing agent used in ultrasound exams of the heart; TechneLite, a technetium generator for nuclear medicine; Xenon-133 to assess pulmonary functiā¦ read more
Healthcare
Drug ManufacturersāSpecialty & Generic
11 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$101.19
Price+1.56%
$1.55
1Y
Price
Market Cap
$6.588b
Mid
Price/Earnings 3y Avg5y Avg
17x
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.+48.8%
EBITDA Margin+31.4%
Net Profit Margin+32.3%
Free Cash Flow Margin+48.8%
EBITDA Margin+31.4%
Net Profit Margin+32.3%
Free Cash Flow MarginRevenue
$1.546b
+0.3%
1y CAGR+6.4%
3y CAGR+14.4%
5y CAGREarnings
$279.031m
+19.5%
1y CAGR-3.4%
3y CAGR+263.4%
5y CAGREPS
$4.15
+21.7%
1y CAGR-2.1%
3y CAGR+264.0%
5y CAGRBook Value
$1.212b
$2.347b
Assets$1.134b
Liabilities$625.752m
DebtDebt to Assets
26.7%
1.3x
Debt to EBITDAFree Cash Flow
$371.695m
+5.0%
1y CAGR+22.5%
3y CAGR+16.4%
5y CAGRNo items found.
Press Releases
Statements and updates from the company